APA |
Banakar, U., & Makoid, M. (2015). Critical considerations in pharmacetical bioequivalence testing. Marmara Pharmaceutical Journal, 11(1-2), 55-80. https://doi.org/10.12991/mpj.20066 |
|
AMA |
Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. Marmara Pharm J. April 2015;11(1-2):55-80. doi:10.12991/mpj.20066 |
|
Chicago |
Banakar, Umesh, and Michael Makoid. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal 11, no. 1-2 (April 2015): 55-80. https://doi.org/10.12991/mpj.20066. |
|
EndNote |
Banakar U, Makoid M (April 1, 2015) Critical considerations in pharmacetical bioequivalence testing. Marmara Pharmaceutical Journal 11 1-2 55–80. |
|
IEEE |
U. Banakar and M. Makoid, “Critical considerations in pharmacetical bioequivalence testing”, Marmara Pharm J, vol. 11, no. 1-2, pp. 55–80, 2015, doi: 10.12991/mpj.20066. |
|
ISNAD |
Banakar, Umesh - Makoid, Michael. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal 11/1-2 (April 2015), 55-80. https://doi.org/10.12991/mpj.20066. |
|
JAMA |
Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. Marmara Pharm J. 2015;11:55–80. |
|
MLA |
Banakar, Umesh and Michael Makoid. “Critical Considerations in Pharmacetical Bioequivalence Testing”. Marmara Pharmaceutical Journal, vol. 11, no. 1-2, 2015, pp. 55-80, doi:10.12991/mpj.20066. |
|
Vancouver |
Banakar U, Makoid M. Critical considerations in pharmacetical bioequivalence testing. Marmara Pharm J. 2015;11(1-2):55-80. |
|